All Posts

Investments in artificial intelligence (AI) for drug discovery are surging. Big Pharmas are throwing big bucks at AI. Sanofi signed …

Without a doubt, the area of artificial intelligence (AI) has been a sensation lately -- judging by the amount of …

Immunotherapies are hot property. Immuno-oncology is the crown jewel. But the road to riches, and more importantly cancer cures, is …

The16th century alchemical and 19th century science fiction revival of a miniature human being in a test tube is undergoing …

Choosing the right biological target or a combination of targets is a fundamental task for any successful drug discovery project. …

The question is often raised, but the answer remains to be uncovered because the definition of drug "target" continues to …

In this interview, Dr. Jackie Hunter, CEO at BenevolentAI, provides insights into how the company’s AI-driven platform helps scientists create …

Consensus seems universal and the news about it flows literally by the minute over gene editing as a future therapy, …

Pharma productivity has remained a daunting challenge, notably because R&D departments have been shuffled and reorganized over the last few …

In a case of "back to the future", chemists at Scripps collaborating with instrument engineers at IKA have unveiled a …

Boston-based LifeMine Therapeutics, a fresh new drug discovery startup, just announced a $55 million Series A financing from a number …

This is an interview with Niels Iversen Møller, a CEO, and Co-founder of Evaxion Biotech -- an immuno-informatics biotech from …